U.S. Supreme Court Rejects J & J Appeal of $2 Billion Talc Verdict

The U.S. Supreme Court rejected a request June 1 from Johnson &Johnson to consider overturning a $2.1 billion award to 22 women who blamed the company’s asbestos-contaminated talcum powder products for causing ovarian cancer. With the Supreme Court declining to consider it, a Missouri state court ruling from 2018 that originally awarded $4.69 billion remains in place. A Missouri court of appeals reduced the award in 2020 to $2.1 billion, but also rejected a J&J effort to dismiss the jury verdict. The appeal did not involve the question of whether the products caused cancer. Johnson &Johnson wanted the Supreme Court to review its argument that the lower courts unfairly combined the 22 cases, which were from several different states with widely different cancer severities and a varied extent of product usage. “The matters that were before the court are related to legal procedure, and not safety,” J&J said in a prepared statement. The court’s action, the statement said, “leaves unresolved significant legal questions that state and federal courts will continue to face on legal issues related to due process rights and personal jurisdiction.” Attorneys for J&J argued that some of the women had family or genetic dispositions for cancer, while others did not. Attorneys for the women maintained that consolidating plaintiffs in product liability cases is common to help preserve court resources. In November, the Missouri Supr...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news

Related Links:

Imagine a world in which physicians can confidently cure cancer. Two Bay Area life sciences companies are working together to make this vision a reality. Atara Biotherapeutics Inc., founded in 2012, is developing a pipeline of cell therapies to treat various types of cancer and autoimmune diseases. Bayer is licensing Atara’s cutting-edge cell therapies that t arget certain types of aggressive tumors including mesothelioma, pancreatic, ovarian and non-small-cell lung cancer. “With cancer therapies,…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
Johnson &Johnson is closer to unloading its talc-related liabilities onto a new subsidiary that could subsequently declare Chapter 11 bankruptcy and dramatically alter the thousands of lawsuits the company is facing. A U.S. Bankruptcy Court judge in the District of Delaware declined requests last week from a panel of personal injury lawyers to prohibit Johnson &Johnson from exercising that option. J&J is facing more than 34,000 lawsuits that link its talc-based products to cancer, the majority of which are ovarian cancer. A small fraction of those lawsuits involve malignant mesothelioma. Most of the lawsui...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
The mesothelioma program at University of Chicago Medicine is recruiting patients for its latest clinical trial involving olaparib, an oral chemotherapy drug targeting cancer-driven genetic mutations. This single-center, phase II clinical trial is open to patients with either pleural mesothelioma or peritoneal mesothelioma. Olaparib, also known by the brand name Lynparza, works by repairing or controlling specific gene mutations. It is known as a protein inhibitor and has been approved by the U.S. Food and Drug Administration for use with breast and ovarian cancers. Mesothelioma, a rare malignancy caused by exposu...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Plaintiff attorneys and congressional leaders have renewed their push against Johnson &Johnson and its allegedly toxic, talc-based powder products, questioning motives and demanding answers, according to various media outlets. A committee of attorneys filed a restraining order in U.S. District Court in Wilmington, Delaware, July 27, hoping to prevent J&J’s potential plan to unload its talc-related liabilities on a new subsidiary that would subsequently file for bankruptcy. The next day, the U.S. House of Representatives Committee on Oversight and Reform delivered a letter to J&J’s chief executive dema...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
This article reviews HIPEC and its targeted intraoperative and postoperative management.
Source: Journal of the American Academy of Physician Assistants - Category: Primary Care Tags: Special Topics in Women's Health Source Type: research
The U.S. Food and Drug Administration has granted orphan drug designation to ONCOFID-P for the treatment of malignant pleural mesothelioma, a step toward another potential therapy option for patients. ONCOFID-P is an innovative drug conjugate already in advanced clinical development for the treatment of invasive bladder cancer. The mesothelioma designation is based on preclinical data showing high antitumor activity in laboratory and mice models. Fidia Farmaceutici, a multinational research company based in Italy, announced the latest FDA designation, which is designed to encourage the development of novel drugs, par...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Johnson &Johnson is considering the creation of a new subsidiary to absorb its widespread asbestos liabilities, according to reports in The Wall Street Journal and other news outlets. The J&J subsidiary would then declare Chapter 11 bankruptcy, potentially saving the multinational corporation billions of dollars. Reuters News Service also reported the subsidiary possibility, citing unnamed personal injury attorneys who learned of the option while negotiating their current claims with J&J officials. A spokesperson for Johnson &Johnson would not confirm the reports.  “Johnson &Johnson Cons...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
A novel, targeted cancer vaccine combined with the immunotherapy drug Opdivo has shown surprising efficacy for mesothelioma patients whose disease no longer responds to standard chemotherapy. In a phase I clinical trial at Memorial Sloan Kettering Cancer Center, the galinpepimut-S vaccine, also known as GPS, has produced an impressive, anti-tumor synergy with Opdivo, based upon early data. GPS targets the WT1 protein, which is expressed in high levels of various cancers but rarely seen in normal adult cells. The protein has been especially resistant to standard chemotherapy. The vaccine works by inducing a powerfu...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
ezza Pezzuto Serio Primary ovarian mesothelioma is a rare, aggressive neoplastic disease with a poor prognosis. At onset, the tumor is only rarely limited to the ovaries and usually already widespread in the peritoneum. The rarity of this entity and the difficulties differentiating it from either ovarian carcinoma or peritoneal mesothelioma may lead to frequent misdiagnoses and may raise some concerns about its histogenesis. Thus, reporting such rare cases is fundamental to gain greater awareness of this neoplasm and try to answer unsolved questions. Herein, we described four cases of histological diagnoses of ov...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Willie McNeal Jr., a Vietnam War veteran and retired school bus driver, was awarded $4.8 million by a California Superior Court jury that determined asbestos-contaminated talc led to his diagnosis of malignant pleural mesothelioma. Whittaker, Clark &Daniels, a longtime talc supplier now based in South Plainfield, New Jersey, was ordered to pay McNeal $1.8 million in compensatory damages and $3 million in punitive damages. The verdict stemmed from evidence presented that an Old Spice powder product, used almost daily by McNeal for more than 20 years, contained talc from a mine in North Carolina known to be contami...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
More News: American Medical Association (AMA) | Asbestosis | Babies | Canada Health | Cancer | Cancer & Oncology | Environmental Health | Food and Drug Administration (FDA) | Genetics | Lawsuits | Legislation | Medical Law | Mesothelioma | Minerals | Ovarian Cancer | Ovaries | Study | Toxicology | Women